U.S. pharma huge copyright scrapped two experimental weight loss drugs very last 12 months—a after-daily capsule, lotiglipron, due to elevated liver enzymes in addition to a twice-every day capsule, danuglipron, on account of solid side effects—but CEO Albert Bourla has said the comp